Humanized Mice Laboratory’s Post

📖Read article: https://lnkd.in/gG_J-Sqj Human papillomavirus (HPV) is the underlying cause of roughly 90% of cervical cancer, making cell-free HPV+ tumor DNA (ctHPV DNA) a promising potential biomarker in the disease. In this article, researchers explored the potential value of ctHPV DNA as a prognostic biomarker and endpoint for earlier relapse detection in locally advanced cervical cancer. Using HPV-type-specific ddPCR assays, the authors found that persistent ctHPV DNA after treatment and during follow-up was strongly correlated with worse progression-free survival. ctHPV DNA was also detected in plasma before radiology diagnosis in all patients who experienced relapse, indicating its potential as a biomarker for early relapse detection. Learn more about the QX600 Droplet Digital™ PCR (ddPCR™) System: https://lnkd.in/grBZGvSt #DropletDigitalPCR #CervicalCancer #HPV #OncologyResearch

ctHPV DNA in follow-up plasma is a promising prognostic biomarker in patients with LACC, useful for analysis of response to therapy and for early detection of relapse using HPV type specific ddPCR assays #ddPCR #ctHPV

Online!📲 Blood-based biomarkers in patients with #nonsmallcelllungcancer treated with #immunecheckpointblockade ------------------------- The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical responses observed among patients poses significant challenges.  To date, analyses of tumor biopsies are the only parameter used to guide prognosis to ICI therapy. Here Jeffrey Schlom, Renee Donahue and YO-TING TSAI review studies in which multiple blood-based biomarkers encompassing circulating soluble analytes, immune cell subsets, circulating tumor DNA, blood-based tumor mutational burden, and circulating tumor cells have shown promising associations with the clinical response of NSCLC patients to ICI therapy. Full text ⤵️ https://lnkd.in/gNcYsVMc #Liquidbiopsy #Immunotherapy IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Cancer mutation supercharges T cells Mutations that let cancer cells thrive when healthy cells would die can boost engineered immune cells’ ability to kill tumours in mice. Engineered chimeric antigen receptor (CAR) T cells are already used to treat blood cancers, but don’t seem to work well for ‘solid’ cancers, such as breast and lung tumours. Researchers screened the effect of 71 mutations found in cancerous T cells, and found that one in particular gave T cells the power to melt away mice’s tumours. Garcia Julie, Daniels J, Lee Y, Zhu I, Cheng K, Liu Q, Goodman D, Burnett C, Law C, Thienpont C, Alavi J, Azimi C, Montgomery G, Roybal KT, Choi J. Naturally occurring T cell mutations enhance engineered T cell therapies. Nature. 2024 February 7. doi: 10.1038/s41586-024-07018-7. PMID: 38326614. https://lnkd.in/g6M2hVcX

Proud to share our published manuscript in Brain, Behavior, and Immunity, in which Pauline Janssen and I studied the role of xCT in pancreatic cancer. This accomplishment is undoubtedly the result of collaborative teamwork. I would therefore like to acknowledge all the co-authors, and especially Ann Massie and Ilse Rooman for their guidance throughout the entire project. Curious about our findings? Read the open access paper via the link below.

In the context of cancer, these proteins participate in diverse processes including angiogenesis, immune response, oxidative stress defense, and immune regulation. Understanding their roles and interactions provides insights into the complex mechanisms underlying cancer biology and can potentially inform the development of targeted therapies and treatment strategies. Featured Antibodies: CD40 Antibody - ABIN7211389 Metallothionein Antibody - ABIN7211696 NRF2 Antibody - ABIN7211413 PDGFRB Antibody - ABIN7211699 Perforin 1 Antibody - ABIN7211704 VEGF Antibody - ABIN7211348 #cancer #hallmarksofcancer #cancerresearch https://lnkd.in/gFWcX3qd

📃Scientific paper: Tumor-to-tumor spread: a case report and literature review of renal cell carcinoma metastasis into thyroid cancer Abstract: Tumor-to-tumor metastasis is a rare, yet important entity. Patients with a history of renal cell carcinoma (RCC) may have tumor deposits to the thyroid gland preceding or following their initial cancer diagnosis for many years. The diagnosis can be challenging, and clinicians must remain suspicious of a newly found thyroid nodule in a patient with a history of RCC. In this review, we report a case of a patient with RCC who was incidentally found to have a thyroid nodule on surveillance imaging found to be consistent with tumor-to-tumor metastasis from RCC into papillary thyroid carcinoma. It is imperative to consider this diagnosis as the thyroid is the most common site of spread, and treatment with partial or total thyroidectomy has led to improved survival. Continued on ES/IODE ➡️ https://etcse.fr/1dXS ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

#Cancer | #NKcells | #CD8Tcells | Killer "Boyz-n-the-Hood" | Breaking Study from Michael Brown, Sepideh Dolatshahi & Friends Posits Harnessing of Both Effector Subsets for More Efficacious #Immunotherapy in #NSCLC 👍 | MHC class I (MHC-I) loss is frequent in non-small cell lung cancer (NSCLC) rendering tumor cells resistant to T cell lysis. NK cells kill MHC-I-deficient tumor cells, and although previous work indicated their presence at NSCLC margins, they were functionally impaired. Here*, Remziye Wessel, Nardin Ageeb, et al evaluated whether NK cell and CD8 T cell infiltration and activation vary with MHC-I expression. They concluded that tumor-infiltrating NK cells and CD8 T cells jointly affected control of NSCLC tumor progression. Co-association of NK and CD8 T cells was most evident in MHC-I-bearing tumors, especially in the presence of IFNγ. Frequent co-localization of IFNγ+ NK cells with other IFNγ+ lymphocytes in near-neighbor analysis suggests NSCLC lymphocyte activation is coordinately regulated. *https://lnkd.in/dkQ3fWkD Celentyx Ltd #immunooncology #drugdiscovery #platforms www.celentyx.com Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady GRAPHICAL ABSTRACT

Characterizing the Tumor Microenvironment of Colorectal Cancer Patients A patient with MSS-type CRC and PD-L1-negative metastases underwent remission and prolonged benefits from immunotherapy after other treatments had previously failed. To investigate the case, TissueFAXS SL was used for whole-slide imaging of tissue sections, and StrataQuest was used to quantify cellular phenotypes based on immune cell markers. Read the white paper here: https://lnkd.in/dfUDSG2Q